Wyzga, formerly the President and CEO of Radius Health, Inc. And, prior to that, the Executive Vice President, Finance and Chief Financial Officer at Genzyme Company First One fourth 2014 Financial Results Akebia reported a net loss of $9.7 million for the first quarter of 2014, in comparison to a net lack of $0.6 million for the 1st quarter of 2013. Net loss applicable to common stockholders, which include accretion on preferred stock of $86.9 million, was $96.6 million for the first quarter of 2014, or per talk about. This compares to a net loss applicable to common stockholders of $1.5 million for the first quarter of 2013, which included accretion on preferred stock of $0.9 million, or per share.And the world. The available choices of FDA-approved smoking cigarettes cessation aids in the U.S. 22nd Century expects, upon FDA approval, that X-22 will be more attractive to smokers than other therapies since X-22 smokes and tastes such as a usual cigarette, consists of the same smoking behavior, and does not expose smokers to fresh drugs or new unwanted effects. Joseph Pandolfino, 22nd Century’s CEO, mentioned, ‘Smokers currently have few options of authorized pharmacotherapies: nicotine , which a large %age of smokers have previously tried and failed to quit smoking, and 2 non-nicotine prescriptions that have a boxed warning.’ half of the 46 million adult smokers in the U Approximately.S.